Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements

HOUSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on October 10, 2025 the Company received notice from the Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), the Equity Standard Requirement. This follows the Company’s announcement on September 9, 2025 that it had regained compliance with Nasdaq Listing Rule 5550(a)(2), the Minimum Bid Price Requirement.

“Salarius is now fully compliant with all Nasdaq listing requirements, marking another critical step in our planned merger with Decoy Therapeutics,” said Mark J. Rosenblum, acting CEO and CFO of Salarius.

On January 13, 2025, Salarius announced it had entered into a definitive merger agreement for a business combination with Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate therapeutics. Under the agreement, Decoy will merge with a wholly owned subsidiary of Salarius, subject to the closing conditions set forth in the agreement. The newly formed company will be named Decoy Therapeutics.

Nasdaq further notified the Company that it will be subject to a Mandatory Panel Monitor for a period of one year from October 10, 2025. If, within that one-year monitoring period, the Listing Qualifications Staff finds the Company out of compliance with the Equity Standard Requirement that was the subject of the exception, the Staff will issue a delisting determination letter and the Company will have the opportunity to request a hearing with the Nasdaq Hearings Panel.

About the Planned Merger
The proposed transaction, if consummated, is expected to facilitate multiple value-creating inflection points with Decoy’s pipeline of peptide conjugate therapeutics engineered by its IMP³ACT^TM platform, which allows for the rapid computational design and manufacturing of innovative peptide conjugate therapeutics. Decoy’s product pipeline targets unmet needs in respiratory infectious diseases and gastroenterology (GI) oncology indications. In addition to advancing the development of Decoy’s IMP³ACT platform, the combined company intends to incorporate Salarius’ oral small molecule protein degrader SP-3164 into a highly targeted peptide-based proteolysis targeting chimeras (PROTACS) drug candidate.